Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Amicus Therapeutics logo — Our passion for making a difference unites us.

Amicus Therapeutics

Our passion for making a difference unites us.

Founded 2002 United States Princeton, United States 604 employees Post-IPO Debt Total: $2.30B Biotechnology, Health Care +2

General Information

Company Name Amicus Therapeutics
Founded Year 2002
Location United States Princeton, United States
Founders / Decision Makers
Team member Team member
Employees 604
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with Amicus Therapeutics. To contact Amicus Therapeutics, visit amicusrx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Amicus Therapeutics compare?

A PDF of Amicus Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Amicus Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Amicus Therapeutics

Amicus Therapeutics is a global, patient-dedicated biotechnology company founded in 2002 and headquartered in the United States. The company's slogan, "Our passion for making a difference unites us," reflects its commitment to discovering, developing, and delivering high-quality medicines for people living with rare metabolic diseases. The company's name, Amicus, reflects its collaborative approach to developing medicines, incorporating the patient perspective at every step. Founded by an entrepreneur driven by a personal experience with rare disease, the company's culture is characterized by empathy, compassion, and tenacity. Amicus's mission-focused behaviors drive its performance and innovation, shaping its culture and attracting top talent. The company's recent investment of $30.00MPost-IPO Equity at 02 October 2023 was led by Blackstone Life Sciences. With a global footprint spanning over 20 countries, Amicus is committed to pushing the boundaries of medical innovation. More information about Amicus and their career opportunities can be found at www.amicusrx.com.

Business keywords: pharmaceuticals, rare diseases, patient-centered, global footprint, innovation, drug discovery, medicine delivery, entrepreneurship, compassion, mission-driven, global headquarters, international presence, career opportunities

Funding Rounds & Investors (15)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt $400.00M 1
Blackstone Credit
02 Oct 2023
Post IPO Equity $30.00M 1
Blackstone Life Sciences
02 Oct 2023
Post IPO Debt $400.00M 1
Hayfin Capital Management
17 Jul 2020
Post IPO Equity $201.00M -
04 Jun 2019
Post IPO Equity $300.00M -
16 Feb 2018
Post IPO Equity $258.80M -
12 Jul 2017
Post IPO Debt $225.00M -
15 Dec 2016
Post IPO Equity $100.00M -
29 Feb 2016
Post IPO Equity $258.80M -
10 Jun 2015
Post IPO Debt $25.00M 3
MidCap Financial
MidCap Financial, Silicon Valley Bank +1
31 Dec 2013

View All 15 Funding Rounds

Amicus Therapeutics Alternatives & Competitors

View All Alternatives
Amicus Therapeutics vs
BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. United States

We develop oral small-molecule and protein therapeutics to treat hereditary angioedema (HAE) and oth...

Post-IPO Debt
608 employees
Biotechnology, Health and Wellness
Compare Amicus Therapeutics vs BioCryst Pharmaceuticals, Inc.
Amicus Therapeutics vs
Autifony Therapeutics
Autifony Therapeutics

Autifony are dedicated to developing new medicines to treat rare genetic CNS disorders

Venture round
37 employees
Biotechnology, Health and Wellness
Compare Amicus Therapeutics vs Autifony Therapeutics
Amicus Therapeutics vs
Arven Pharmaceuticals
Arven Pharmaceuticals Turkey

Hücreden Bitmiş Ürüne- Biyoteknoloji

97 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About Amicus Therapeutics

Our passion for making a difference unites us.
Amicus Therapeutics was founded in 2002.
Amicus Therapeutics is headquartered in Princeton, United States.
Amicus Therapeutics operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical. Its work centres on pharmaceuticals, rare diseases, patient-centered and global footprint.
Amicus Therapeutics has approximately 604 employees.
Amicus Therapeutics has completed 15 funding rounds, raising a total of $2.30B. The latest funding stage is Post-IPO Debt.
Top alternatives and competitors to Amicus Therapeutics include BioCryst Pharmaceuticals, Inc., Autifony Therapeutics, Arven Pharmaceuticals, Pharming Group, Blue Turtle Bio Technologies, Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Amicus Therapeutics and BioCryst Pharmaceuticals, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Amicus Therapeutics, https://bouncewatch.com/company/amicus-therapeutics, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes